Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma